皮下司美格鲁肽联合强化行为治疗对超重或肥胖成人减重的随机临床试验
STEP 3 是一项在美国 41 个中心开展的随机、双盲、平行组、68 周 3a 期研究,纳入 611 例无糖尿病的超重或肥胖成人。受试者按 2:1 随机接受每周一次皮下司美格鲁肽 2.4 mg(n=407)或安慰剂(n=204),均联合前 8 周低热量饮食及 68 周强化行为治疗(30 次咨询访视)。第 68 周时,司美格鲁肽组体重较基线平均变化 -16.0%,安慰剂组 -5.7%,组间差异 -10.3 个百分点(95%CI -12.0 至 -8.6;P<.001);司美格鲁肽组减重≥5%、≥10%、≥15% 的比例分别为 86.6%、75.3%、55.8%,均显著高于安慰剂组的 47.6%、27.0%、13.2%(P<.001)。胃肠道不良事件在司美格鲁肽组更常见(82.8% vs 63.2%),因不良事件停药比例为 3.4% vs 0%。
要点
- 司美格鲁肽 2.4 mg 联合强化行为治疗 68 周平均减重 16.0%,安慰剂联合行为治疗减重 5.7%。
- 司美格鲁肽组减重≥5%、≥10%、≥15% 的比例分别为 86.6%、75.3%、55.8%。
- 胃肠道不良事件更常见(82.8% vs 63.2%),因不良事件停药 3.4% vs 0%。
核心结论
- 在超重或肥胖成人中,每周一次皮下司美格鲁肽 2.4 mg 联合强化行为治疗及初始低热量饮食,较安慰剂联合相同干预在 68 周内实现显著更大的体重下降。
- 需进一步研究评估该减重效果的持久性。
研究设计与样本
- 随机、双盲、平行组、68 周 3a 期研究(STEP 3),于 2018 年 8 月至 2020 年 4 月在美国 41 个中心开展。
- 纳入 611 例无糖尿病的成人,符合超重(BMI≥27)且至少 1 种合并症或肥胖(BMI≥30);按 2:1 随机分配至司美格鲁肽 2.4 mg 组(n=407)或安慰剂组(n=204)。
- 两组均联合前 8 周低热量饮食及 68 周强化行为治疗(30 次咨询访视)。
- 共同主要终点为第 68 周体重较基线百分比变化及减重≥5% 的比例。
主要发现
- 第 68 周体重较基线估计平均变化:司美格鲁肽组 -16.0%,安慰剂组 -5.7%,组间差异 -10.3 个百分点(95%CI -12.0 至 -8.6;P<.001)。
- 减重≥5% 的比例:司美格鲁肽组 86.6%,安慰剂组 47.6%(P<.001)。
- 减重≥10% 的比例:司美格鲁肽组 75.3%,安慰剂组 27.0%(P<.001)。
- 减重≥15% 的比例:司美格鲁肽组 55.8%,安慰剂组 13.2%(P<.001)。
- 胃肠道不良事件发生率:司美格鲁肽组 82.8%,安慰剂组 63.2%;因胃肠道不良事件停药比例分别为 3.4% 和 0%。
关键数值与推荐
- 司美格鲁肽 2.4 mg 每周一次皮下注射联合强化行为治疗用于无糖尿病超重或肥胖成人减重。
- 共同主要终点为第 68 周体重百分比变化及减重≥5% 的比例。
临床怎么用
- 对无糖尿病的超重或肥胖成人,可考虑每周一次皮下司美格鲁肽 2.4 mg 作为强化行为治疗和初始低热量饮食的辅助以增强减重效果。
- 用药期间需关注胃肠道不良事件,本研究中司美格鲁肽组胃肠道不良事件发生率 82.8%,因不良事件停药比例 3.4%。
局限性
- 研究为期 68 周,减重效果的持久性尚需进一步研究评估。
- 研究纳入无糖尿病的超重或肥胖成人,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches. OBJECTIVE: To compare the effects of once-weekly subcutaneous semaglutide, 2.4 mg vs placebo for weight management as an adjunct to intensive behavioral therapy with initial low-calorie diet in adults with overweight or obesity. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, 68-week, phase 3a study (STEP 3) conducted at 41 sites in the US from August 2018 to April 2020 in adults without diabetes (N = 611) and with either overweight (body mass index ≥27) plus at least 1 comorbidity or obesity (body mass index ≥30). INTERVENTIONS: Participants were randomized (2:1) to semaglutide, 2.4 mg (n = 407) or placebo (n = 204), both combined with a low-calorie diet for the first 8 weeks and intensive behavioral therapy (ie, 30 counseling visits) during 68 weeks. MAIN OUTCOMES AND MEASURES: The co-primary end points were percentage change in body weight and the loss of 5% or more of baseline weight by week 68. Confirmatory secondary end points included losses of at least 10% or 15% of baseline weight. RESULTS: Of 611 randomized participants (495 women [81.0%], mean age 46 years [SD, 13], body weight 105.8 kg [SD, 22.9], and body mass index 38.0 [SD, 6.7]), 567 (92.8%) completed the trial, and 505 (82.7%) were receiving treatment at trial end. At week 68, the estimated mean body weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo (difference, -10.3 percentage points [95% CI, -12.0 to -8.6]; P < .001). More participants treated with semaglutide vs placebo lost at least 5% of baseline body weight (86.6% vs 47.6%, respectively; P < .001). A higher proportion of participants in the semaglutide vs placebo group achieved weight losses of at least 10% or 15% (75.3% vs 27.0% and 55.8% vs 13.2%, respectively; P < .001). Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%). Treatment was discontinued owing to these events in 3.4% of semaglutide participants vs 0% of placebo participants. CONCLUSIONS AND RELEVANCE: Among adults with overweight or obesity, once-weekly subcutaneous semaglutide compared with placebo, used as an adjunct to intensive behavioral therapy and initial low-calorie diet, resulted in significantly greater weight loss during 68 weeks. Further research is needed to assess the durability of these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03611582.
引用
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476. doi:10.1001/jama.2021.1831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。